ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Roblox Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – RBLX

Rosen Law Firm is encouraging investors who purchased shares of Roblox Corporation between October 30, 2025 and April 30, 2026 to join a securities class action lawsuit. The firm alleges that Roblox made materially false and misleading statements regarding its organic growth potential, concealing that enrollment in age verification would cause significant growth slowdown, reduced app store ratings, and diminished organic growth. The lead plaintiff deadline is August 7, 2026. The firm is also investigating potential securities claims for Embecta Corp. and TruBridge, Inc.

06/22/2026, 8:28 PM • GlobeNewswire

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Embecta Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EMBC

Rosen Law Firm has filed a class action lawsuit against Embecta Corp. on behalf of investors who purchased common stock between November 25, 2025 and May 4, 2026. The lawsuit alleges that Embecta made false and misleading statements about its fiscal results and guidance, specifically regarding its pen needle business, which it described as 'incredibly resolute' before missing expectations and cutting 2026 guidance. Investors who purchased during this period may be entitled to compensation. The deadline to serve as lead plaintiff is August 17, 2026.

06/22/2026, 7:24 PM • GlobeNewswire

Shareholders who lost money in shares of Embecta Corp. (NASDAQ: EMBC) Should Contact Wolf Haldenstein Immediately

A securities fraud class action has been filed against Embecta Corp. (NASDAQ: EMBC) for providing overwhelmingly positive statements while concealing poor fiscal results. The company touted strong pen needle business performance before missing guidance and cutting 2026 fiscal guidance. On May 5, 2026, Embecta revealed a 14% revenue decline and lowered full-year guidance, causing the stock to plummet 57.8% in a single day from $9.25 to $3.90 per share. Investors who purchased shares between November 25, 2025 and May 4, 2026 may be eligible to participate in the class action.

06/22/2026, 6:43 PM • GlobeNewswire

Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business -- HBSS

Embecta Corp. (EMBC) faces a securities class action lawsuit for allegedly misleading investors about the stability of its pen needle business. The company provided optimistic guidance in February 2026 but reported a 61% sequential EPS decline in Q2 2026, slashed full-year guidance by 43%, and cut its dividend by 93%, triggering a significant stock selloff. Investors are being urged to report losses as the investigation examines when management knew about revenue headwinds.

06/19/2026, 3:19 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Embecta Corp. alleging that company executives made materially false and misleading statements about business operations and guidance during the Class Period (November 25, 2025 - May 4, 2026). The complaint claims Embecta misrepresented its pen needle business as 'incredibly resolute' before missing Q2 2026 guidance and cutting full-year guidance, with revenue declining over 14% versus guidance of flat to 2% decline.

06/19/2026, 12:00 PM • GlobeNewswire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Embecta Corp. Common Stock and Sets a Lead Plaintiff Deadline of August 17, 2026

Law firm Levi & Korsinsky has filed a class action lawsuit against Embecta Corp. for allegedly providing misleading guidance and concealing material adverse facts about its fiscal results. The company's stock plummeted 57.8% on May 5, 2026, after revealing a 14% revenue decline and lowering 2026 guidance, particularly due to weakness in pen needle sales. The lead plaintiff deadline is set for August 17, 2026.

06/17/2026, 12:58 PM • GlobeNewswire

embecta to Participate in Investor Events

Embecta Corp. (Nasdaq: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced its participation in four major investor conferences in June 2026, including the Jefferies Global Healthcare Conference, TD Cowen Diabetes Tech Summit, Goldman Sachs Global Healthcare Conference, and Truist Securities MedTech Conference. The company will host one-on-one meetings and a fireside session to engage with investors.

06/01/2026, 5:00 PM • GlobeNewswire

EMBC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Embecta Corp.

Law firm Kirby McInerney LLP is investigating Embecta Corp. following the company's May 5, 2026 earnings report that missed analyst expectations and included reduced full-year guidance. The announcement cited losses in pen needle products at a major customer and market softness in insulin pens. Embecta's stock price plummeted 58% from $9.25 to $3.90 per share on the news. The investigation seeks to determine if federal securities laws were violated.

05/27/2026, 8:00 PM • GlobeNewswire

embecta Completes Acquisition of Owen Mumford Holdings Limited

Embecta Corp (NASDAQ: EMBC) has completed its acquisition of Owen Mumford Holdings Limited, a UK-based medical device manufacturer. The deal, announced in March 2026, includes an upfront payment of £100 million plus up to £50 million in performance-based payments. The acquisition accelerates embecta's transformation into a broad-based medical supplies company with expanded drug delivery platforms and chronic care device portfolios across obesity, diabetes, autoimmune diseases, and anaphylaxis markets.

05/15/2026, 9:00 AM • Benzinga

Why Embecta Stock Plummeted Today

Embecta's stock crashed 57.8% following disappointing fiscal Q2 2026 results. The medical-device company reported adjusted EPS of $0.27 on sales of $221.8 million, significantly missing analyst expectations of $0.42 EPS and $235.7 million in sales. Sales declined 14.4% year-over-year with EBITDA margins compressing to 29.1% from 37.5%. The company substantially lowered full-year guidance for both sales and adjusted operating margins, raising concerns about near-term growth prospects.

05/05/2026, 8:19 PM • The Motley Fool

embecta Announces Quarterly Cash Dividend

Embecta Corp (NASDAQ: EMBC) announced a quarterly cash dividend of $0.01 per share, payable on June 15, 2026 to shareholders of record as of May 28, 2026. The company continues its legacy in insulin delivery while expanding into broader medical supplies.

05/05/2026, 6:30 AM • Benzinga

embecta to Report Fiscal Second Quarter Financial Results

Embecta Corp. (Nasdaq: EMBC) announced it will host a conference call on May 5, 2026, at 8:00 a.m. ET to discuss its fiscal second quarter 2026 financial results and provide an operational update. The global medical supplies company, with a 100-year legacy in insulin delivery, will also hold a question and answer session accessible via live webcast and teleconference.

04/21/2026, 5:00 PM • GlobeNewswire

Embecta Rallies After UK Firm Deal Worth $200 Million

Embecta agreed to acquire Owen Mumford Holdings Limited for up to $200 million (150 million pounds), including a $134 million upfront payment and up to $67 million in performance-based payments. The acquisition aims to enhance Embecta's drug-delivery capabilities and expand into chronic care markets. The deal is expected to close in Q3 fiscal 2026 and contribute to revenue growth from fiscal 2027 onward, though it will be dilutive to adjusted net income in 2027. Embecta shares rose 4.63% to $8.98 on the announcement.

03/19/2026, 11:37 AM • Benzinga

embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited

Embecta Corp has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device and drug-delivery technology company, for up to £150 million (£100 million upfront plus up to £50 million in performance-based payments). The acquisition is expected to expand embecta's product portfolio, accelerate growth in chronic care markets, and leverage complementary manufacturing capabilities and global commercial infrastructure.

03/19/2026, 6:30 AM • Benzinga

3 Healthcare Stocks Paying the Highest Dividends of 2026

The article examines three high-yielding healthcare stocks: Perrigo (8.2% yield) is cautioned as a potential value trap despite strong dividend history; Pfizer (6.7% yield) is viewed more favorably with post-COVID catalysts and GLP-1 product launches; Embecta (5.5% yield) shows turnaround potential as it pivots toward the GLP-1 pen needle business.

02/06/2026, 3:15 PM • The Motley Fool